| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14656566.7.15.2019 |
| P698 | PubMed publication ID | 17020429 |
| P2093 | author name string | James Hedrick | |
| P2860 | cites work | In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci | Q24550612 |
| Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors | Q30310410 | ||
| Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve | Q33181940 | ||
| A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients | Q34408275 | ||
| Practice guidelines for the diagnosis and management of skin and soft-tissue infections | Q34460523 | ||
| Cefditoren pivoxil: a review of its use in the treatment of bacterial infections | Q35933736 | ||
| Staphylococcal skin infections in children: rational drug therapy recommendations | Q36116435 | ||
| Ceftobiprole: in-vivo profile of a bactericidal cephalosporin | Q36416472 | ||
| BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis | Q39650937 | ||
| High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections | Q39708441 | ||
| Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk | Q41714469 | ||
| Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes | Q42107999 | ||
| Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials | Q44012054 | ||
| Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections | Q44104700 | ||
| Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children | Q44190469 | ||
| Mechanistic basis for the action of new cephalosporin antibiotics effective against methicillin- and vancomycin-resistant Staphylococcus aureus | Q44419760 | ||
| Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy | Q44604616 | ||
| Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection | Q44686515 | ||
| Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients | Q44905295 | ||
| Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: a sample of North American isolates | Q45020146 | ||
| Cefdinir: an oral alternative to parenteral cephems | Q46420076 | ||
| Methicillin-resistant Staphylococcus aureus disease in three communities | Q46426018 | ||
| Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles | Q46426023 | ||
| Community-associated MRSA--resistance and virulence converge | Q46426027 | ||
| Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children | Q46585229 | ||
| A pooled analysis of seven randomized crossover studies of the palatability of cefdinir oral suspension versus amoxicillin/clavulanate potassium, cefprozil, azithromycin, and amoxicillin in children aged 4 to 8 years | Q46968394 | ||
| Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group. | Q53830093 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2019-2024 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Cephalosporins for uncomplicated skin and skin structure infections in emerging community-acquired MRSA. | |
| P478 | volume | 7 |
Search more.